Validation of SELDI-TOF MS serum protein profiles for renal cell carcinoma in new populations

Laboratory Investigation

Volumn 87, Issue 2, 2007, Pages 161-172

  Engwegen, Judith Y M N ^a   Mehra, Niven ^b   Haanen, John B A G ^c   Bonfrer, Johannes M G ^c   Schellens, Jan H M ^c,d   Voest, Emile E ^b   Beijnen, Jos H ^a,d  

^a SLOTERVAART HOSPITAL   (Netherlands)

^b UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^c ANTONI VAN LEEUWENHOEK HOSPITAL   (Netherlands)

^d UTRECHT UNIVERSITY   (Netherlands)

Author keywords

Biomarker; Renal cell carcinoma; Reproducibility; SELDI TOF MS; Validation

Indexed keywords

BIOLOGICAL MARKER; SERUM AMYLOID A;

ADULT; ARTICLE; CANCER PATIENT; CLINICAL ARTICLE; CLUSTER ANALYSIS; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; KIDNEY CARCINOMA; MALE; NEPHRECTOMY; PATIENT CODING; PRIORITY JOURNAL; PROTEIN EXPRESSION; SERUM; SURFACE ENHANCED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; VALIDATION STUDY;

ADULT; BIOLOGICAL MARKERS; BLOOD PROTEINS; CARCINOMA, RENAL CELL; CASE-CONTROL STUDIES; COMPUTATIONAL BIOLOGY; ENZYME-LINKED IMMUNOSORBENT ASSAY; EVALUATION STUDIES AS TOPIC; FEMALE; HUMANS; MALE; MIDDLE AGED; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION;

EID: 33847209996     PISSN: 00236837     EISSN: 15300307     Source Type: Journal    
DOI: 10.1038/labinvest.3700503     Document Type: Article

References (34)

1. Cohen HT, McGovern FJ. Renal-cell carcinoma. N Engl J Med 2005;353:2477-2490.
2. Fung ET, Thulasiraman V, Weinberger SR, et al. Protein biochips for differential profiling. Curr Opin Biotechnol 2001;12:65-69.
3. Issaq HJ, Veenstra TD, Conrads TP, et al. The SELDI-TOF MS approach to proteomics: protein profiling and biomarker identification. Biochem Biophys Res Commun 2002;292:587-592.
4. Zhang Z, Bast Jr RC, Yu Y, et al. Three biomarkers identified from serum proteomic analysis for the detection of early stage ovarian cancer. Cancer Res 2004;64:5882-5890.
5. Li J, Zhang Z, Rosenzweig J, et al. Proteomics and bioinformatics approaches for identification of serum biomarkers to detect breast cancer. Clin Chem 2002;48:1296-1304.
6. Adam BL, Qu Y, Davis JW, et al. Serum protein fingerprinting coupled with a pattern-matching algorithm distinguishes prostate cancer from benign prostate hyperplasia and healthy men. Cancer Res 2002;62:3609-3614.
7. Chen YD, Zheng S, Yu JK, et al. Artificial neural networks analysis of surface-enhanced laser desorption/ionization mass spectra of serum protein pattern distinguishes colorectal cancer from healthy population. Clin Cancer Res 2004;10:8380-8385.
8. Tolson J, Bogumil R, Brunst E, et al. Serum protein profiling by SELDI mass spectrometry: detection of multiple variants of serum amyloid alpha in renal cancer patients. Lab Invest 2004;84:845-856.
9. Won Y, Song HJ, Kang TW, et al. Pattern analysis of serum proteome distinguishes renal cell carcinoma from other urologic diseases and healthy persons. Proteomics 2003;3:2310-2316.
10. Baggerly KA, Morris JS, Coombes KR. Reproducibility of SELDI-TOF protein patterns in serum: comparing datasets from different experiments. Bioinformatics 2004;20:777-785.
11. Diamandis EP. Re: diagnostic potential of serum proteomic patterns in prostate cancer. J Urol 2004;171:1244-1245.
12. Diamandis EP, van der Merwe D-E. Plasma protein profiling by mass spectrometry for cancer diagnosis: opportunities and limitations. Clin Cancer Res 2005;11:963-965.
13. Diamandis EP. Point: proteomic patterns in biological fluids: do they represent the future of cancer diagnostics? Clin Chem 2003;49:1272-1275.
14. Petricoin EF, Liotta LA. Counterpoint: the vision for a new diagnostic paradigm. Clin Chem 2003;49:1276-1278.
15. Baggerly KA, Morris JS, Edmonson SR, et al. Signal in noise: evaluating reported reproducibility of serum proteomic tests for ovarian cancer. J Natl Cancer Inst 2005;97:307-309.
16. Liotta LA, Lowenthal M, Mehta A, et al. Importance of communication between producers and consumers of publicly available experimental data. J Natl Cancer Inst 2005;97:310-314.
17. Sorace JM, Zhan M. A data review and re-assessment of ovarian cancer serum proteomic profiling. BMC Bioinformatics 2003;4:24. Available from URL: http://www.biomedcentral.com/1471-2105/4/24.
18. Diamandis EP. Mass spectrometry as a diagnostic and a cancer biomarker discovery tool: opportunities and potential limitations. Mol Cell Proteomics 2004;3:367-378.
19. Grizzle WE, Meleth S, Petricoin EF, et al. Clarification in the point/counterpoint discussion related to surface-enhanced laser desorption/ionization time-of-flight mass spectrometric identification of patients with adenocarcinomas of the prostate. Clin Chem 2004;50:1475-1477.
20. Li J, Orlandi R, White CN, et al. Independent validation of candidate breast cancer serum biomarkers identified by mass spectrometry. Clin Chem 2005;51:2229-2235.
21. Mathelin C, Cromer A, Wendling C, et al. Serum biomarkers for detection of breast cancers: a prospective study. Breast Cancer Res Treat 2006;96:83-90.
22. Grizzle WE, Adam BL, Bigbee WL, et al. Serum protein expression profiling for cancer detection: validation of a SELDI-based approach for prostate cancer. Dis Markers 2003;19:185-195.
23. Grizzle WE, Semmes OJ, Basler J, et al. The early detection research network surface-enhanced laser desorption and ionization prostate cancer detection study: a study in biomarker validation in genitourinary oncology. Urol Oncol 2004;22:337-343.
24. Fung ET, Yip TT, Lomas L, et al. Classification of cancer types by measuring variants of host response proteins using SELDI serum assays. Int J Cancer 2005;115:783-789.
25. Le L, Chi K, Tyldesley S, et al. Identification of serum amyloid A as a biomarker to distinguish prostate cancer patients with bone lesions. Clin Chem 2005;51:695-707.
26. Moshkovskii SA, Serebryakova MV, Kuteykin-Teplyakov KB, et al. Ovarian cancer marker of 11.7 kDa detected by proteomics is a serum amyloid A1. Proteomics 2005;5:3790-3797.
27. Cho WC, Yip TT, Yip C, et al. Identification of serum amyloid a protein as a potentially useful biomarker to monitor relapse of nasopharyngeal cancer by serum proteomic profiling. Clin Cancer Res 2004;10:43-52.
28. Langlois RG, Trebes JE, Dalmasso EA, et al. Serum protein profile alterations in hemodialysis patients. Am J Nephrol 2004;24:268-274.
29. Honda K, Hayashida Y, Umaki T, et al. Possible detection of pancreatic cancer by plasma protein profiling. Cancer Res 2005;65:10613-10622.
30. Yu JK, Chen YD, Zheng S. An integrated approach to the detection of colorectal cancer utilizing proteomics and bioinformatics. World J Gastroenterol 2004;10:3127-3131.
31. Hara T, Honda K, Ono M, et al. Identification of 2 serum biomarkers of renal cell carcinoma by surface enhanced laser desorption/ionization mass spectrometry. J Urol 2005;174:1213-1217.
32. Banez LL, Prasanna P, Sun L, et al. Diagnostic potential of serum proteomic patterns in prostate cancer. J Urol 2003;170:442-446.
33. Koomen JM, Shih LN, Coombes KR, et al. Plasma protein profiling for diagnosis of pancreatic cancer reveals the presence of host response proteins. Clin Cancer Res 2005;11:1110-1118.
34. Gourin CG, Xia ZS, Han Y, et al. Serum protein profile analysis in patients with head and neck squamous cell carcinoma. Arch Otolaryngol Head Neck Surg 2006;132:390-397.